You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Mounjaro® (tirzepatide) be used in patients with thyroid diseases other than thyroid cancer?
Tirzepatide is contraindicated in patients with MEN 2 or a personal or family history of MTC. Eli Lilly and Company has not studied the efficacy and safety of tirzepatide in patients with other thyroid diseases.
See important safety information, including boxed warning, in the attached prescribing information.
Use in Patients With Thyroid Disease/Abnormalities
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).1
There is no information on the use of tirzepatide in people with thyroid disease/abnormalities, including hypothyroidism or hyperthyroidism, because this has not been studied by Eli Lilly and Company.
People with controlled endocrine disorders could participate in the tirzepatide studies for type 2 diabetes. Patients were excluded from the SURPASS 1-5 and SURPASS-CVOT phase 3 clinical studies if they had
- evidence of a significant, uncontrolled endocrine abnormality (eg, thyrotoxicosis or adrenal crises), in the opinion of the investigator, or
- a serum calcitonin level of
- ≥35 ng/L (SURPASS -1, -2, -3, and -5), or
- ≥20 ng/L if eGFR ≥60 mL/min/1.73 m2 and ≥35 ng/L if eGFR <60 mL/min/1.73 m2 (SURPASS-4 and SURPASS-CVOT).2-7
Please refer to Mounjaro (tirzepatide) prescribing information for any contraindications or additional information on whether to use tirzepatide in patients with thyroid diseases/abnormalities. Lilly cannot provide recommendations beyond the approved prescribing information. The healthcare practitioner may use the patient’s prior medical history and concomitant medications, and other individual factors when developing a treatment plan. The healthcare practitioner should consider potential risks and benefits of treatment options and monitor appropriately.
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
2Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736%2821%2901324-6
3Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519
4Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4
5Del Prato S, Kahn SE, Pavo I, et al; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7
6Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545. https://doi.org/10.1001/jama.2022.0078
7Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1-11. https://doi.org/10.1016/j.ahj.2023.09.007
Date of Last Review: January 07, 2026